|
1
|
Cowan AJ, Allen C, Barac A, Basaleem H,
Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, et
al: Global burden of multiple myeloma: A systematic analysis for
the global burden of disease study 2016. JAMA Oncol. 4:1221–1227.
2018.
|
|
2
|
Kumar SK, Dimopoulos MA, Kastritis E,
Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M,
Alsina M, et al: Natural history of relapsed myeloma, refractory to
immunomodulatory drugs and proteasome inhibitors: A multicenter
IMWG study. Leukemia. 31:2443–2448. 2017.
|
|
3
|
van de Donk N, Pawlyn C and Yong KL:
Multiple myeloma. Lancet. 397:410–427. 2021.
|
|
4
|
Birney E, Stamatoyannopoulos JA, Dutta A,
Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis
ET, Thurman RE, et al: Identification and analysis of functional
elements in 1% of the human genome by the ENCODE pilot project.
Nature. 447:799–816. 2007.
|
|
5
|
Yan H and Bu P: Non-coding RNA in cancer.
Essays. Biochem. 65:625–639. 2021.
|
|
6
|
Winkle M, Kluiver JL, Diepstra A and van
den Berg A: Emerging roles for long noncoding RNAs in B-cell
development and malignancy. Crit Rev Oncol Hematol. 120:77–85.
2017.
|
|
7
|
Li Y, Li G, Guo X, Yao H, Wang G and Li C:
Non-coding RNA in bladder cancer. Cancer Lett. 485:38–44. 2020.
|
|
8
|
Statello L, Guo CJ, Chen LL and Huarte M:
Gene regulation by long non-coding RNAs and its biological
functions. Nat Rev Mol Cell Biol. 22:96–118. 2021.
|
|
9
|
Zhu J, Fu H, Wu Y and Zheng X: Function of
lncRNAs and approaches to lncRNA-protein interactions. Sci China
Life Sci. 56:876–885. 2013.
|
|
10
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018.
|
|
11
|
Sun Q, Hao Q and Prasanth KV: Nuclear long
noncoding RNAs: Key regulators of gene expression. Trends Genet.
34:142–157. 2018.
|
|
12
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017.
|
|
13
|
Kazandjian D: Multiple myeloma
epidemiology and survival: A unique malignancy. Semin Oncol.
43:676–681. 2016.
|
|
14
|
Goyal B, Yadav SRM, Awasthee N, Gupta S,
Kunnumakkara AB and Gupta SC: Diagnostic, prognostic, and
therapeutic significance of long non-coding RNA MALAT1 in cancer.
Biochim Biophys Acta Rev Cancer. 1875:1885022021.
|
|
15
|
Sun Y, Jiang T, Jia Y, Zou J, Wang X and
Gu W: LncRNA MALAT1/miR-181a-5p affects the proliferation and
adhesion of myeloma cells via regulation of Hippo-YAP signaling
pathway. Cell Cycle. 18:2509–2523. 2019.
|
|
16
|
Liu H, Chi Z, Jin H and Yang W: MicroRNA
miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates
cell proliferation and apoptosis in multiple myeloma.
Bioengineered. 12:1611–1626. 2021.
|
|
17
|
Ghafouri-Fard S, Esmaeili M and Taheri M:
H19 lncRNA: Roles in tumorigenesis. Biomed Pharmacother.
123:1097742020.
|
|
18
|
Zheng JF, Guo NH, Zi FM and Cheng J: Long
noncoding RNA H19 promotes tumorigenesis of multiple myeloma by
activating BRD4 signaling by targeting MicroRNA 152-3p. Mol Cell
Biol. 40:e00382–19. 2020.
|
|
19
|
Xiong T, Li J, Chen F and Zhang F: PCAT-1:
A novel oncogenic long non-coding RNA in human cancers. Int J Biol
Sci. 15:847–856. 2019.
|
|
20
|
Shen X, Kong S, Yang Q, Yin Q, Cong H,
Wang X and Ju S: PCAT-1 promotes cell growth by sponging miR-129
via MAP3K7/NF-κB pathway in multiple myeloma. J Cell Mol Med.
24:3492–3503. 2020.
|
|
21
|
Onagoruwa OT, Pal G, Ochu C and Ogunwobi
OO: Oncogenic role of PVT1 and therapeutic implications. Front
Oncol. 10:172020.
|
|
22
|
Yang M, Zhang L, Wang X, Zhou Y and Wu S:
Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma
promotes cell proliferation. Arch Med Sci. 14:1333–1339. 2018.
|
|
23
|
Wang M, Zhao HY, Zhang JL, Wan DM, Li YM
and Jiang ZX: Dysregulation of LncRNA ANRIL mediated by miR-411-3p
inhibits the malignant proliferation and tumor stem cell like
property of multiple myeloma via hypoxia-inducible factor 1α. Exp
Cell Res. 396:1122802020.
|
|
24
|
Meng YB, He X, Huang YF, Wu QN, Zhou YC
and Hao DJ: Long noncoding RNA CRNDE promotes multiple myeloma cell
growth by suppressing miR-451. Oncol Res. 25:1207–1214. 2017.
|
|
25
|
Liu Q, Ran R, Song M, Li X, Wu Z, Dai G
and Xia R: LncRNA HCP5 acts as a miR-128-3p sponge to promote the
progression of multiple myeloma through activating
Wnt/β-catenin/cyclin D1 signaling via PLAGL2. Cell Biol Toxicol.
38:979–993. 2022.
|
|
26
|
Liu H, Shen Y, Xu Y, Wang L, Zhang C,
Jiang Y, Hong L, Huang H and Liu H: lncRNA transcription factor 7
is related to deteriorating clinical features and poor prognosis in
multiple myeloma, and its knockdown suppresses disease progression
by regulating the miR-203-mediated Jagged1-Notch1 signaling
pathway. Oncol Lett. 21:4122021.
|
|
27
|
Ding T, Deng R and Huang T: Long
non-coding RNA T cell factor 7 is associated with increased disease
risk and poor prognosis, and promotes cell proliferation,
attenuates cell apoptosis and miR-200c expression in multiple
myeloma. Oncol Lett. 21:1292021.
|
|
28
|
Xiao X, Gu Y, Wang G and Chen S: c-Myc,
RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell
proliferation and apoptosis in multiple myeloma. Int J Biol
Macromol. 122:526–537. 2019.
|
|
29
|
Liu Z, Han M, Meng N, Luo J and Fu R:
lncRNA MSTRG.29039.1 promotes proliferation by sponging
hsa-miR-12119 via JAK2/STAT3 pathway in multiple myeloma. Oxid Med
Cell Longev. 2021:99694492021.
|
|
30
|
Wang F, Luo Y, Zhang L, Younis M and Yuan
L: The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the
proliferation and apoptosis of multiple myeloma cancer cells via
the PI3K/AKT signalling pathway. Cancer Gene Ther. 29:292–303.
2022.
|
|
31
|
Chen X, Liu Y, Yang Z, Zhang J, Chen S and
Cheng J: LINC01234 promotes multiple myeloma progression by
regulating miR-124-3p/GRB2 axis. Am J Transl Res. 11:6600–6618.
2019.
|
|
32
|
Deng M, Yuan H, Liu S, Hu Z and Xiao H:
Exosome-transmitted LINC00461 promotes multiple myeloma cell
proliferation and suppresses apoptosis by modulating microRNA/BCL-2
expression. Cytotherapy. 21:96–106. 2019.
|
|
33
|
Chu M, Fan Y, Wu L, Ma X, Sao J, Yao Y,
Zhuang W and Zhang C: Knockdown of lncRNA BDNF-AS inhibited the
progression of multiple myeloma by targeting the
miR-125a/b-5p-BCL2axis. Immun Ageing. 19:32022.
|
|
34
|
Yang Y and Chen L: Downregulation of
lncRNA UCA1 facilitates apoptosis and reduces proliferation in
multiple myeloma via regulation of the miR-1271-5p/HGF axis. J Chin
Med Assoc. 82:699–709. 2019.
|
|
35
|
Li QY, Chen L, Hu N and Zhao H: Long
non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma
via miR-610/Akt3 axis. Biomed Pharmacother. 103:1727–1732.
2018.
|
|
36
|
Chen L, Hu N, Wang C, Zhao H and Gu Y:
Long non-coding RNA CCAT1 promotes multiple myeloma progression by
acting as a molecular sponge of miR-181a-5p to modulate HOXA1
expression. Cell Cycle. 17:319–329. 2018.
|
|
37
|
Fu Y, Liu X, Zhang F, Jiang S, Liu J and
Luo Y: Bortezomib-inducible long non-coding RNA myocardial
infarction associated transcript is an oncogene in multiple myeloma
that suppresses miR-29b. Cell Death Dis. 10:3192019.
|
|
38
|
Sun Y, Pan J, Zhang N, Wei W, Yu S and Ai
L: Knockdown of long non-coding RNA H19 inhibits multiple myeloma
cell growth via NF-κB pathway. Sci Rep. 7:180792017.
|
|
39
|
Shen X, Shen P, Yang Q, Yin Q, Wang F,
Cong H, Wang X and Ju S: Knockdown of long non-coding RNA PCAT-1
inhibits myeloma cell growth and drug resistance via p38 and JNK
MAPK pathways. J Cancer. 10:6502–6510. 2019.
|
|
40
|
Handa H, Honma K, Oda T, Kobayashi N,
Kuroda Y, Kimura-Masuda K, Watanabe S, Ishihara R, Murakami Y,
Masuda Y, et al: Long Noncoding RNA PVT1 is regulated by
bromodomain protein BRD4 in multiple myeloma and is associated with
disease progression. Int J Mol Sci. 21:71212020.
|
|
41
|
Ronchetti D, Todoerti K, Vinci C, Favasuli
V, Agnelli L, Manzoni M, Pelizzoni F, Chiaramonte R, Platonova N,
Giuliani N, et al: Expression pattern and biological significance
of the lncRNA ST3GAL6-AS1 in multiple myeloma. Cancers (Basel).
12:7822020.
|
|
42
|
Geng W, Guo X, Zhang L, Ma Y, Wang L, Liu
Z, Ji H and Xiong Y: Resveratrol inhibits proliferation, migration
and invasion of multiple myeloma cells via NEAT1-mediated
Wnt/β-catenin signaling pathway. Biomed Pharmacother. 107:484–494.
2018.
|
|
43
|
Zhu BZ and Lin L: Effects of lncRNA HOTAIR
on proliferation and apoptosis of myeloma cells through NF-κB
pathway. Eur Rev Med Pharmacol Sci. 23:10042–10048. 2019.
|
|
44
|
Liu Z, Gao H, Peng Q and Yang Y: Long
noncoding RNA LUCAT1 promotes multiple myeloma cell growth by
regulating the TGF-β signaling pathway. Technol Cancer Res Treat.
19:15330338209457702020.
|
|
45
|
Shen Q, Jiang Q, Cong Z, Zhou Y, Huang X,
Zhu L, Xu X and Qian J: Knockdown of lncRNA AL928768.3 inhibits
multiple myeloma cell proliferation by inducing cell cycle arrest
in G0/G1 phase. Ann Transl Med. 10:1722022.
|
|
46
|
Chen R, Zhang X and Wang C: LncRNA
HOXB-AS1 promotes cell growth in multiple myeloma via FUT4 mRNA
stability by ELAVL1. J Cell Biochem. 121:4043–4051. 2020.
|
|
47
|
Jia H, Liu Y, Lv S, Qiao R, Zhang X, Niu
F, Shang W, Liu S, Dong J and Zhang Z: LBX2-AS1 as a novel
diagnostic biomarker and therapeutic target facilitates multiple
myeloma progression by enhancing mRNA stability of LBX2. Front Mol
Biosci. 8:7065702021.
|
|
48
|
Halazonetis TD, Gorgoulis VG and Bartek J:
An oncogene-induced DNA damage model for cancer development.
Science. 319:1352–1355. 2008.
|
|
49
|
Kar S: Unraveling cell-cycle dynamics in
cancer. Cell Systems. 2:8–10. 2016.
|
|
50
|
Basu AK: DNA damage, mutagenesis and
cancer. Int J Mol Sci. 19:9702018.
|
|
51
|
Larsen BD, Benada J, Yung PYK, Bell RAV,
Pappas G, Urban V, Ahlskog JK, Kuo TT, Janscak P, Megeney LA, et
al: Cancer cells use self-inflicted DNA breaks to evade growth
limits imposed by genotoxic stress. Science. 376:476–483. 2022.
|
|
52
|
Hu Y, Lin J, Fang H, Fang J, Li C, Chen W,
Liu S, Ondrejka S, Gong Z, Reu F, et al: Targeting the
MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in
multiple myeloma. Leukemia. 32:2250–2262. 2018.
|
|
53
|
Sharma S, Javadekar SM, Pandey M,
Srivastava M, Kumari R and Raghavan SC: Homology and enzymatic
requirements of microhomology-dependent alternative end joining.
Cell Death Dis. 6:e16972015.
|
|
54
|
Huambachano O, Herrera F, Rancourt A and
Satoh MS: Double-stranded DNA binding domain of poly(ADP-ribose)
polymerase-1 and molecular insight into the regulation of its
activity. J Biol Chem. 286:7149–7160. 2011.
|
|
55
|
Taiana E, Favasuli V, Ronchetti D,
Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S,
Silvestris I, Gallo Cantafio ME, et al: Long non-coding RNA NEAT1
targeting impairs the DNA repair machinery and triggers anti-tumor
activity in multiple myeloma. Leukemia. 34:234–244. 2020.
|
|
56
|
Gao D, Lv AE, Li HP, Han DH and Zhang YP:
LncRNA MALAT-1 elevates HMGB1 to promote autophagy resulting in
inhibition of tumor cell apoptosis in multiple myeloma. J Cell
Biochem. 118:3341–3348. 2017.
|
|
57
|
Yang X, Huang H, Wang X, Liu H, Liu H and
Lin Z: Knockdown of lncRNA SNHG16 suppresses multiple myeloma cell
proliferation by sponging miR-342-3p. Cancer Cell Int.
20:382020.
|
|
58
|
Hamidi H and Ivaska J: Every step of the
way: Integrins in cancer progression and metastasis. Nat Rev
Cancer. 18:533–548. 2018.
|
|
59
|
Ganapathy-Kanniappan S and Geschwind JF:
Tumor glycolysis as a target for cancer therapy: Progress and
prospects. Mol Cancer. 12:1522013.
|
|
60
|
Liu N, Feng S, Li H, Chen X, Bai S and Liu
Y: Long non-coding RNA MALAT1 facilitates the tumorigenesis,
invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13
axis. J Cancer Res Clin Oncol. 146:367–379. 2020.
|
|
61
|
Tianhua Y, Dianqiu L, Xuanhe Z, Zhe Z and
Dongmei G: Long non-coding RNA Sox2 overlapping transcript (SOX2OT)
promotes multiple myeloma progression via microRNA-143-3p/c-MET
axis. J Cell Mol Med. 24:5185–5194. 2020.
|
|
62
|
He X, Fan X, Zhang B, Wu L and Wu X:
Expression of LINC01606 in multiple myeloma and its effect on cell
invasion and migration. Am J Transl Res. 13:8777–8786. 2021.
|
|
63
|
Shen Y, Feng Y, Li F, Jia Y, Peng Y, Zhao
W, Hu J and He A: lncRNA ST3GAL6-AS1 promotes invasion by
inhibiting hnRNPA2B1-mediated ST3GAL6 expression in multiple
myeloma. Int J Oncol. 58:52021.
|
|
64
|
Xiao Y and Yu D: Tumor microenvironment as
a therapeutic target in cancer. Pharmacol Ther. 221:1077532021.
|
|
65
|
Hinshaw DC and Shevde LA: The tumor
microenvironment innately modulates cancer progression. Cancer Res.
79:4557–4566. 2019.
|
|
66
|
Gao Y, Fang P, Li WJ, Zhang J, Wang GP,
Jiang DF and Chen FP: LncRNA NEAT1 sponges miR-214 to regulate M2
macrophage polarization by regulation of B7-H3 in multiple myeloma.
Mol Immunol. 117:20–28. 2020.
|
|
67
|
Wang Z, He J, Bach DH, Huang YH, Li Z, Liu
H, Lin P and Yang J: Induction of m6A methylation in
adipocyte exosomal LncRNAs mediates myeloma drug resistance. J Exp
Clin Cancer Res. 41:42022.
|
|
68
|
Wu L, Xia L, Chen X, Ruan M, Li L and Xia
R: Long non-coding RNA LINC01003 suppresses the development of
multiple myeloma by targeting miR-33a-5p/PIM1 axis. Leuk Res.
106:1065652021.
|
|
69
|
Yang N, Chen J, Zhang H, Wang X, Yao H,
Peng Y and Zhang W: LncRNA OIP5-AS1 loss-induced microRNA-410
accumulation regulates cell proliferation and apoptosis by
targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple
myeloma. Cell Death Dis. 8:e29752017.
|
|
70
|
Wang Y, Wang H, Ruan J, Zheng W, Yang Z
and Pan W: Long non-coding RNA OIP5-AS1 suppresses multiple myeloma
progression by sponging miR-27a-3p to activate TSC1 expression.
Cancer Cell Int. 20:1552020.
|
|
71
|
Wu L, Xia L, Jiang H, Hu Y, Li L, Xu L and
Xia R: Long non-coding RNA DANCR represses the viability, migration
and invasion of multiple myeloma cells by sponging miR-135b-5p to
target KLF9. Mol Med Rep. 24:6492021.
|
|
72
|
Jiang Y, Chen J and Chen G: Long noncoding
RNA IRAIN acts as tumor suppressor via miR-125b in multiple
myeloma. Oncol Lett. 18:6787–6794. 2019.
|
|
73
|
Pu J, Huang H, Su J, Yuan J, Cong H, Wang
X and Ju S: Decreased expression of long noncoding RNA XLOC_013703
promotes cell growth via NF-κB pathway in multiple myeloma. IUBMB
Life. 71:1240–1251. 2019.
|
|
74
|
Li Z, Kumar S, Jin DY, Calin GA, Chng WJ,
Siu KL, Poon MW and Chim CS: Epigenetic silencing of long
non-coding RNA BM742401 in multiple myeloma: Impact on prognosis
and myeloma dissemination. Cancer Cell Int. 20:4032020.
|
|
75
|
Fechtner K, Hillengass J, Delorme S, Heiss
C, Neben K, Goldschmidt H, Kauczor HU and Weber MA: Staging
monoclonal plasma cell disease: Comparison of the Durie-Salmon and
the Durie-Salmon PLUS staging systems. Radiology. 257:195–204.
2010.
|
|
76
|
Shen Y, Feng Y, Chen H, Huang L, Wang F,
Bai J, Yang Y, Wang J, Zhao W, Jia Y, et al: Focusing on long
non-coding RNA dysregulation in newly diagnosed multiple myeloma.
Life Sci. 196:133–142. 2018.
|
|
77
|
Pan Y, Chen H, Shen X, Wang X, Ju S, Lu M
and Cong H: Serum level of long noncoding RNA H19 as a diagnostic
biomarker of multiple myeloma. Clin Chim Acta. 480:199–205.
2018.
|
|
78
|
Yin Q, Shen X, Cui X and Ju S: Elevated
serum lncRNA TUG1 levels are a potential diagnostic biomarker of
multiple myeloma. Exp Hematol. 79:47–55.e42. 2019.
|
|
79
|
Xiao G, Li Y, Wang Y, Zhao B, Zou Z, Hou
S, Jia X, Liu X, Yao Y, Wan J, et al: LncRNA PRAL is closely
related to clinical prognosis of multiple myeloma and the
bortezomib sensitivity. Exp Cell Res. 370:254–263. 2018.
|
|
80
|
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey
DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and
management of multiple myeloma: A review. JAMA. 327:464–477.
2022.
|
|
81
|
Rossi D, Fangazio M, De Paoli L, Puma A,
Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G and Gaidano
G: Beta-2-microglobulin is an independent predictor of progression
in asymptomatic multiple myeloma. Cancer. 116:2188–2200. 2010.
|
|
82
|
Kim JE, Yoo C, Lee DH, Kim SW, Lee JS and
Suh C: Serum albumin level is a significant prognostic factor
reflecting disease severity in symptomatic multiple myeloma. Ann
Hematol. 89:391–397. 2010.
|
|
83
|
Kyle RA, Gertz MA, Witzig TE, Lust JA,
Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson
DR, et al: Review of 1027 patients with newly diagnosed multiple
myeloma. Mayo Clin Proc. 78:21–33. 2003.
|
|
84
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–34202. 2005.
|
|
85
|
Yin Y, Yang W, Zhang L, Liu K and Luo Z:
Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a,
microRNA-125a and microRNA-186) relate to risk stratification and
prognosis in multiple myeloma. Hematology. 26:160–169. 2021.
|
|
86
|
Yu H, Peng S, Chen X, Han S and Luo J:
Long non-coding RNA NEAT1 serves as a novel biomarker for treatment
response and survival profiles via microRNA-125a in multiple
myeloma. J Clin Lab Anal. 34:e233992020.
|
|
87
|
Sedlarikova L, Gromesova B, Kubaczkova V,
Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi
M, Penka M, et al: Deregulated expression of long non-coding RNA
UCA1 in multiple myeloma. Eur J Haematol. 99:223–233. 2017.
|
|
88
|
Zhao P and Zhao X: Baseline lncRNA PCAT1
high expression and its longitude increment during induction
therapy predict worse prognosis in multiple myeloma patients. J
Clin Lab Anal. 35:e239242021.
|
|
89
|
Dong H, Jiang S, Fu Y, Luo Y, Gui R and
Liu J: Upregulation of lncRNA NR_046683 serves as a prognostic
biomarker and potential drug target for multiple myeloma. Front
Pharmacol. 10:452019.
|
|
90
|
Zhou F and Guo L: Lncrna ANGPTL1-3 and its
target microRNA-30a exhibit potency as biomarkers for bortezomib
response and prognosis in multiple myeloma patients. Hematology.
27:596–602. 2022.
|
|
91
|
Xu H, Yin Q, Shen X and Ju S: Long
non-coding RNA CCAT2 as a potential serum biomarker for diagnosis
and prognosis of multiple myeloma. Ann Hematol. 99:2159–2171.
2020.
|
|
92
|
Dimopoulos MA, Barlogie B, Smith TL and
Alexanian R: High serum lactate dehydrogenase level as a marker for
drug resistance and short survival in multiple myeloma. Ann Intern
Med. 115:931–935. 1991.
|
|
93
|
Shouval R, Teper O, Fein JA, Danylesko I,
Shem Tov N, Yerushalmi R, Avigdor A, Vasilev E, Magen H, Nagler A,
et al: LDH and renal function are prognostic factors for long-term
outcomes of multiple myeloma patients undergoing allogeneic
hematopoietic stem cell transplantation. Bone Marrow Transplant.
55:1736–1743. 2020.
|
|
94
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015.
|
|
95
|
Sedlarikova L, Bollova B, Radova L,
Brozova L, Jarkovsky J, Almasi M, Penka M, Kuglík P, Sandecká V,
Stork M, et al: Circulating exosomal long noncoding RNA PRINS-First
findings in monoclonal gammopathies. Hematol Oncol. 36:786–791.
2018.
|
|
96
|
Terpos E, Zamagni E, Lentzsch S, Drake MT,
García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F,
de la Rubia J, Kyriakou C, et al: Treatment of multiple
myeloma-related bone disease: Recommendations from the Bone Working
Group of the International Myeloma Working Group. Lancet Oncol.
22:e119–e130. 2021.
|
|
97
|
Dimopoulos MA, Sonneveld P, Leung N,
Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski
RZ, Powles R, et al: International Myeloma working group
recommendations for the diagnosis and management of myeloma-related
renal impairment. J Clin Oncol. 34:1544–1557. 2016.
|
|
98
|
Sonneveld P, Avet-Loiseau H, Lonial S,
Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle
RA, et al: Treatment of multiple myeloma with high-risk
cytogenetics: A consensus of the International Myeloma Working
Group. Blood. 127:2955–2962. 2016.
|
|
99
|
Röllig C, Knop S and Bornhäuser M:
Multiple myeloma. Lancet. 385:2197–2208. 2015.
|
|
100
|
Yang LH, Du P, Liu W, An LK, Li J, Zhu WY,
Yuan S, Wang L and Zang L: LncRNA ANRIL promotes multiple myeloma
progression and bortezomib resistance by EZH2-mediated
epigenetically silencing of PTEN. Neoplasma. 68:788–797. 2021.
|
|
101
|
Paiva B, van Dongen JJ and Orfao A: New
criteria for response assessment: Role of minimal residual disease
in multiple myeloma. Blood. 125:3059–3068. 2015.
|
|
102
|
Gay F, Larocca A, Wijermans P, Cavallo F,
Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM,
Siniscalchi A, et al: Complete response correlates with long-term
progression-free and overall survival in elderly myeloma treated
with novel agents: Analysis of 1175 patients. Blood. 117:3025–3031.
2011.
|
|
103
|
Ignatiadis M, Sledge GW and Jeffrey SS:
Liquid biopsy enters the clinic-implementation issues and future
challenges. Nat Rev Clin Oncol. 18:297–312. 2021.
|
|
104
|
Allegra A, Cancemi G, Mirabile G, Tonacci
A, Musolino C and Gangemi S: Circulating tumour cells, cell free
DNA and tumour-educated platelets as reliable prognostic and
management biomarkers for the liquid biopsy in multiple myeloma.
Cancers (Basel). 14:41362022.
|
|
105
|
Wallington-Beddoe CT and Mynott RL:
Prognostic and predictive biomarker developments in multiple
myeloma. J Hematol Oncol. 14:1512021.
|
|
106
|
Shen X, Zhang Y, Wu X, Guo Y, Shi W, Qi J,
Cong H, Wang X, Wu X and Ju S: Upregulated lncRNA-PCAT1 is closely
related to clinical diagnosis of multiple myeloma as a predictive
biomarker in serum. Cancer Biomark. 18:257–263. 2017.
|
|
107
|
Guan R, Wang W, Fu B, Pang Y, Lou Y and Li
H: Increased lncRNA HOTAIR expression promotes the chemoresistance
of multiple myeloma to dexamethasone by regulating cell viability
and apoptosis by mediating the JAK2/STAT3 signaling pathway. Mol
Med Rep. 20:3917–3923. 2019.
|
|
108
|
Yu W, Hurley J, Roberts D, Chakrabortty
SK, Enderle D, Noerholm M, Breakefield XO and Skog JK:
Exosome-based liquid biopsies in cancer: Opportunities and
challenges. Ann Oncol. 32:466–477. 2021.
|
|
109
|
Kumar SK, Rajkumar V, Kyle RA, van Duin M,
Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma.
Nat Rev Dis Primers. 3:170462017.
|
|
110
|
Kumar SK, Dispenzieri A, Lacy MQ, Gertz
MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et
al: Continued improvement in survival in multiple myeloma: Changes
in early mortality and outcomes in older patients. Leukemia.
28:1122–1128. 2014.
|
|
111
|
Dimopoulos MA, Richardson PG, Moreau P and
Anderson KC: Current treatment landscape for relapsed and/or
refractory multiple myeloma. Nat Rev Clin Oncol. 12:42–54.
2015.
|
|
112
|
Obeng EA, Carlson LM, Gutman DM,
Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce
a terminal unfolded protein response in multiple myeloma cells.
Blood. 107:4907–4916. 2006.
|
|
113
|
Davis LN and Sherbenou DW: Emerging
therapeutic strategies to overcome drug resistance in multiple
myeloma. Cancers (Basel). 13:16862021.
|
|
114
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011.
|
|
115
|
Pinto V, Bergantim R, Caires HR, Seca H,
Guimarães JE and Vasconcelos MH: Multiple myeloma: Available
therapies and causes of drug resistance. Cancers (Basel).
12:4072020.
|
|
116
|
Yang X, Ye H, He M, Zhou X, Sun N, Guo W,
Lin X, Huang H, Lin Y, Yao R, et al: LncRNA PDIA3P interacts with
c-Myc to regulate cell proliferation via induction of pentose
phosphate pathway in multiple myeloma. Biochem Biophys Res Commun.
498:207–213. 2018.
|
|
117
|
Pan Y, Zhang Y, Liu W, Huang Y, Shen X,
Jing R, Pu J, Wang X, Ju S, Cong H, et al: LncRNA H19
overexpression induces bortezomib resistance in multiple myeloma by
targeting MCL-1 via miR-29b-3p. Cell Death Dis. 10:1062019.
|
|
118
|
Che F, Ye X, Wang Y, Ma S and Wang X: Lnc
NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate
bortezomib resistance in human multiple myeloma cells. Eur J
Pharmacol. 891:1737522021.
|
|
119
|
Chauhan D and Anderson KC: Mechanisms of
cell death and survival in multiple myeloma (MM): Therapeutic
implications. Apoptosis. 8:337–343. 2003.
|
|
120
|
Wu Y and Wang H: LncRNA NEAT1 promotes
dexamethasone resistance in multiple myeloma by targeting
miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:2018 View Article : Google Scholar
|
|
121
|
David A, Zocchi S, Talbot A, Choisy C,
Ohnona A, Lion J, Cuccuini W, Soulier J, Arnulf B, Bories JC, et
al: The long non-coding RNA CRNDE regulates growth of multiple
myeloma cells via an effect on IL6 signalling. Leukemia.
35:1710–1721. 2021.
|
|
122
|
Voorhees PM, Jakubowiak AJ, Kumar SK,
Kanapuru B, Baines AC, Bhatnagar V, Ershler R, Theoret MR, Gormley
NJ and Pazdur R: Perspectives on drug development in multiple
myeloma-looking forward to 2025. Clin Cancer Res. 28:23–26.
2022.
|
|
123
|
Gupta A, Andresen JL, Manan RS and Langer
R: Nucleic acid delivery for therapeutic applications. Adv Drug
Deliv Rev. 178:1138342021.
|
|
124
|
Kulkarni JA, Witzigmann D, Thomson SB,
Chen S, Leavitt BR, Cullis PR and van der Meel R: The current
landscape of nucleic acid therapeutics. Nat Nanotechnol.
16:630–643. 2021.
|
|
125
|
K C RB, Thapa B, Valencia-Serna J,
Aliabadi HM and Uludağ H: Nucleic acid combinations: A new frontier
for cancer treatment. J Control Release. 256:153–169. 2017.
|
|
126
|
Amodio N, Stamato MA, Juli G, Morelli E,
Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E,
et al: Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene
expression of proteasome subunits and triggers anti-multiple
myeloma activity. Leukemia. 32:1948–1957. 2018.
|
|
127
|
Anashkina AA, Leberfarb EY and Orlov YL:
Recent trends in cancer genomics and bioinformatics tools
development. Int J Mol Sci. 22:121462021.
|
|
128
|
Zheng H, Talukder A, Li X and Hu H: A
systematic evaluation of the computational tools for lncRNA
identification. Brief Bioinform. 22:bbab2852021.
|
|
129
|
Duan Y, Zhang W, Cheng Y, Shi M and Xia
XQ: A systematic evaluation of bioinformatics tools for
identification of long noncoding RNAs. RNA. 27:80–98. 2021.
|
|
130
|
Herman AB, Tsitsipatis D and Gorospe M:
Integrated lncRNA function upon genomic and epigenomic regulation.
Mol Cell. 82:2252–2266. 2022.
|
|
131
|
Volders PJ, Anckaert J, Verheggen K,
Nuytens J, Martens L, Mestdagh P and Vandesompele J: LNCipedia 5:
Towards a reference set of human long non-coding RNAs. Nucleic
Acids Res. 47:D135–D139. 2019.
|
|
132
|
Ma L, Cao J, Liu L, Du Q, Li Z, Zou D,
Bajic VB and Zhang Z: LncBook: A curated knowledgebase of human
long non-coding RNAs. Nucleic Acids Res. 47:D128–D134. 2019.
|
|
133
|
Chen J, Zhang J, Gao Y, Li Y, Feng C, Song
C, Ning Z, Zhou X, Zhao J, Feng M, et al: LncSEA: A platform for
long non-coding RNA related sets and enrichment analysis. Nucleic
Acids Res. 49:D969–D980. 2021.
|
|
134
|
Li Z, Liu L, Jiang S, Li Q, Feng C, Du Q,
Zou D, Xiao J, Zhang Z and Ma L: LncExpDB: An expression database
of human long non-coding RNAs. Nucleic Acids Res. 49:D962–D968.
2021.
|
|
135
|
Xie F, Liu S, Wang J, Xuan J, Zhang X, Qu
L, Zheng L and Yang J: deepBase v3.0: Expression atlas and
interactive analysis of ncRNAs from thousands of deep-sequencing
data. Nucleic Acids Res. 49:D877–D883. 2021.
|
|
136
|
Li J, Han L, Roebuck P, Diao L, Liu L,
Yuan Y, Weinstein JN and Liang H: TANRIC: An interactive open
platform to explore the function of lncRNAs in cancer. Cancer Res.
75:3728–3737. 2015.
|
|
137
|
Zheng Y, Xu Q, Liu M, Hu H, Xie Y, Zuo Z
and Ren J: lnCAR: A Comprehensive resource for lncRNAs from cancer
arrays. Cancer Res. 79:2076–2083. 2019.
|
|
138
|
Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q and
Dong D: LncRNADisease 2.0: An updated database of long non-coding
RNA-associated diseases. Nucleic Acids Res. 47:D1034–D1037.
2019.
|
|
139
|
Li Y, Li L, Wang Z, Pan T, Sahni N, Jin X,
Wang G, Li J, Zheng X, Zhang Y, et al: LncMAP: Pan-cancer atlas of
long noncoding RNA-mediated transcriptional network perturbations.
Nucleic Acids Res. 46:1113–1123. 2018.
|
|
140
|
Gong J, Liu W, Zhang J, Miao X and Guo AY:
lncRNASNP: A database of SNPs in lncRNAs and their potential
functions in human and mouse. Nucleic Acids Res. 43:D181–D186.
2015.
|
|
141
|
Zhi H, Li X, Wang P, Gao Y, Gao B, Zhou D,
Zhang Y, Guo M, Yue M, Shen W, et al: Lnc2Meth: A manually curated
database of regulatory relationships between long non-coding RNAs
and DNA methylation associated with human disease. Nucleic Acids
Res. 46:D133–D138. 2018.
|
|
142
|
Todoerti K, Ronchetti D, Puccio N,
Silvestris I, Favasuli V, Amodio N, Gentile M, Morabito F, Neri A
and Taiana E: Dissecting the biological relevance and clinical
impact of lncRNA MIAT in multiple myeloma. Cancers (Basel).
13:55182021.
|
|
143
|
Zhou M, Zhao H, Wang Z, Cheng L, Yang L,
Shi H, Yang H and Sun J: Identification and validation of potential
prognostic lncRNA biomarkers for predicting survival in patients
with multiple myeloma. J Exp Clin Cancer Res. 34:1022015.
|
